Q-omics provides the consensus-scored VPS37C profile across patient tissues and cancer cell-line models. VPS37C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, VPS37C is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, VPS37C RNA expression shows 20,286 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where VPS37C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS37C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS37C survival associations across molecular data types. VPS37C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS37C RNA expression–survival associations across cancer types. High VPS37C expression shows unfavorable associations in LIHC, BLCA, ACC and PAAD, but favorable associations in LUAD and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for VPS37C RNA expression.
This table summarizes VPS37C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for VPS37C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS37C shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, COAD, BRCA and BLCA. The HNSC box plot shows higher VPS37C RNA expression in tumor versus normal tissue (log2 FC = +0.538, t-test p < 0.001).
This table shows molecular features associated with VPS37C in patient tissues and cancer cell lines. In patient samples, VPS37C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS37C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
